As real world evidence (RWE) becomes a more prevalent resource for confirming and expanding product benefit-risk profiles, non-randomized studies (NRS) are emerging as a valuable generator of real world data (RWD). Joan Largent – Senior Director, Epidemiology and Outcomes Research at IQVIA – discusses the findings of her recent study and how researchers can utilize assessment tools for their ability to accurately assess NRS validity.
Cosette Pharmaceuticals Inc., a New Jersey-based pharmaceutical company, announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).
Mike Hidock, Director of Quality and Compliance Services at IQVIA, analyzes key considerations for preparing quality management systems (QMS) for fast tracked COVID-19 treatment approvals.
Total global spending on Covid-19 vaccines is projected to reach $157 billion by 2025, driven by mass vaccination programs underway and “booster shots” expected every two years, according to a report by U.S. health data company IQVIA Holdings Inc. released on April 29.
Netherlands-based Mylan is buying the intellectual property and commercialization rights to Aspen Pharmacare’s thrombosis business in Europe for €641.9 million ($757.3 million).
Life sciences company IQVIA Holdings Inc. will collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
Among many of the insights provided in the IQVIA Institute for Human Data Science report “Global Medicine Spending and Usage Trends: Outlook to 2024,” global medicine spending is projected to increase from 2 percent to 5 percent annually through 2024 on a net basis, compared to 4.2 percent in the past five years.
Veeva Systems announced that the company is gaining widespread customer support for an antitrust lawsuit against IQVIA. Six of the largest global pharmaceutical companies were among more than 70 depositions gathered as part of the fact discovery phase of the case.
The U.S. Food and Drug Administration called for Eisai to pull the company’s Belviq and Belviq XR for weight loss from the market after clinical trials demonstrated an increased incidence of cancer in users.
AstraZeneca is significantly expanding the company’s footprint in China with the establishment of a global R&D center and launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.